Literature DB >> 31904086

Utility of claims data for identification of date of diagnosis of brain metastases.

Nayan Lamba1, Rachel B Kearney1, Elie Mehanna1, Paul J Catalano2, Daphne A Haas-Kogan1, Daniel N Cagney1, Ayal A Aizer1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 31904086      PMCID： PMC7158642          DOI： 10.1093/neuonc/noz245

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Utility of administrative claims data for the study of brain metastases: a validation study.

Authors:  April F Eichler; Elizabeth B Lamont
Journal:  J Neurooncol       Date:  2009-06-27       Impact factor: 4.130

2.  CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

Authors:  Bernhard C Pestalozzi; Eileen Holmes; Evandro de Azambuja; Otto Metzger-Filho; Laurence Hogge; Matt Scullion; István Láng; Andrew Wardley; Mikhail Lichinitser; Roberto I Lopez Sanchez; Volkmar Müller; David Dodwell; Richard D Gelber; Martine J Piccart-Gebhart; David Cameron
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

3.  Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.

Authors:  Vinai Gondi; Stephanie L Pugh; Wolfgang A Tome; Chip Caine; Ben Corn; Andrew Kanner; Howard Rowley; Vijayananda Kundapur; Albert DeNittis; Jeffrey N Greenspoon; Andre A Konski; Glenn S Bauman; Sunjay Shah; Wenyin Shi; Merideth Wendland; Lisa Kachnic; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

4.  Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.

Authors:  Paul D Brown; Karla V Ballman; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Anthony C Whitton; Jeffrey Greenspoon; Ian F Parney; Nadia N I Laack; Jonathan B Ashman; Jean-Paul Bahary; Costas G Hadjipanayis; James J Urbanic; Fred G Barker; Elana Farace; Deepak Khuntia; Caterina Giannini; Jan C Buckner; Evanthia Galanis; David Roberge
Journal:  Lancet Oncol       Date:  2017-07-04       Impact factor: 41.316

Review 5.  The pathogenesis and treatment of brain metastases: a comprehensive review.

Authors:  Alicia Tosoni; Mario Ermani; Alba A Brandes
Journal:  Crit Rev Oncol Hematol       Date:  2004-12       Impact factor: 6.312

Review 6.  Brain Metastases.

Authors:  Ayal A Aizer; Eudocia Q Lee
Journal:  Neurol Clin       Date:  2018-06-18       Impact factor: 3.806
  6 in total
  9 in total

1.  Hospice Utilization in Elderly Patients With Brain Metastases.

Authors:  Elie K Mehanna; Paul J Catalano; Daniel N Cagney; Daphne A Haas-Kogan; Brian M Alexander; James A Tulsky; Ayal A Aizer
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

2.  Population-based estimates of survival among elderly patients with brain metastases.

Authors:  Nayan Lamba; Rachel Brigell Kearney; Paul J Catalano; Michael J Hassett; Patrick Y Wen; Daphne A Haas-Kogan; Ayal A Aizer
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

3.  Utility of claims data for delineation of intracranial treatment among patients with brain metastases.

Authors:  Nayan Lamba; Paul J Catalano; Daphne A Haas-Kogan; Patrick Y Wen; Ayal A Aizer
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

4.  Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: A population- and institutional-level analysis.

Authors:  Nayan Lamba; Fang Cao; Daniel N Cagney; Paul J Catalano; Daphne A Haas-Kogan; Patrick Y Wen; Ayal A Aizer
Journal:  Neurooncol Pract       Date:  2021-11-01

5.  Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis.

Authors:  Nayan Lamba; Paul J Catalano; Colleen Whitehouse; Kate L Martin; Mallika L Mendu; Daphne A Haas-Kogan; Patrick Y Wen; Ayal A Aizer
Journal:  Neurooncol Pract       Date:  2021-05-21

6.  Readmission risk of malignant brain tumor patients undergoing laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB): a covariate balancing weights analysis of the National Readmissions Database (NRD).

Authors:  Truong H Do; Madeleine A Howard; Elise F Palzer; Jared D Huling; Mohammed A Alvi; Samuel W Cramer; Ping Zhu; Reid A Johnson; James Jean; Jinci Lu; Alec B Jonason; Jacob Hanson; Luke Sabal; Kevin W Sun; Robert A McGovern; Clark C Chen
Journal:  J Neurooncol       Date:  2022-07-23       Impact factor: 4.506

Review 7.  Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.

Authors:  Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2022-10-03       Impact factor: 13.029

8.  Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis.

Authors:  Nayan Lamba; Elie Mehanna; Rachel B Kearney; Paul J Catalano; Daphne A Haas-Kogan; Brian M Alexander; Daniel N Cagney; Kathleen A Lee; Ayal A Aizer
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

9.  Seizures Among Patients with Brain Metastases: A Population- and Institutional-level Analysis.

Authors:  Nayan Lamba; Paul J Catalano; Daniel N Cagney; Daphne A Haas-Kogan; Ellen J Bubrick; Patrick Y Wen; Ayal A Aizer
Journal:  Neurology       Date:  2021-01-05       Impact factor: 9.910
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.